Podcasts about Melanoma

Making strides against melanoma: how can medical oncologists and interventional oncologists join forces to deliver smarter, patient-centered care? In this episode of BackTable, Dr. Tyler Sandow, hosts Dr. Sunandana Chandra, medical oncologist at Northwestern, and Dr. Riad Salem, interventional oncologist at Northwestern to discuss the evolving management of advanced melanoma. --- This podcast is supported by an educational grant from Replimune. --- SYNPOSIS The doctors open the episode with an overview of melanoma and recent advances in its treatment, highlighting key trials such as DREAMseq and CheckMate 067. The discussion explores the shift from medical oncologist as solo primary providers to a dynamic, multidisciplinary approach to advanced cancer care—emphasizing cutting-edge treatments like immunotherapy and intratumoral oncolytic viruses. Dr. Salem shares practical insights on the procedural techniques of administering intratumoral oncolytics like Replimune, emphasizing the importance of thorough documentation and patient-centered care. The doctors also provide an overview of the ongoing IGNYTE-3 Trial, a Phase 3 study assessing the safety and efficacy of the oncolytic immunotherapy RP1 in combination with nivolumab for the treatment of advanced melanoma. The episode underscores the transformative potential of innovative melanoma treatments and the crucial role of integrated, team-based approaches in improving cancer patient outcomes. --- TIMESTAMPS 00:00 - Introduction03:48 - The Evolution of Melanoma Treatment: From Chemotherapy to Immunotherapy14:05 - The Role of Oncolytic Viruses in Melanoma Treatment20:14 - Interventional Radiology's Role in Cancer Treatment27:00 - Collaborative Approach to Cancer Care32:53 - Hyper Documentation and Communication Efficiency44:47 - Future of Intratumoral Oncolytics48:10 - Multidisciplinary Approach in Advanced Cancer Management51:46 - Conclusion and Final Thoughts --- RESOURCES DREAMseq Trial: Atkins MB, Lee SJ, Chmielowski B, et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186-197. doi:10.1200/JCO.22.01763 CheckMate 067 trial: Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2025;392(1):11-22. doi:10.1056/NEJMoa2407417

Hello Sunday is a skincare brand on a mission to make SPF a daily essential, not just a beach-day afterthought. Founded by Amy Ford after spending years under the intense Australian sun, the brand was born from her realization that sun protection is crucial year-round—even on cloudy days in the UK. Amy returned home with a clear vision: to create affordable, effective SPF products that combine skincare benefits with broad-spectrum protection. She teamed up with a dedicated group of skincare lovers and formulation experts to bring that vision to life. Hello Sunday's formulas are designed to fit seamlessly into any routine, promoting healthy, protected skin every day because every day is a SUN day.In this episode, Amy also discusses:The risk of exposure to UV rays even at low levelsBeing new and different merging skincare and sun careExpensive doesn't mean betterWhy using SPF is the #1 thing you can do for your skin to age healthily Entering in the US in Sephora and growing in this marketWe hope you enjoy this episode and gain valuable insights into Amy's journey and the growth of www.us.hellosundayspf.com. Don't forget to subscribe to the Glam & Grow podcast for more in-depth conversations with the most incredible brands, founders, and more.Be sure to check out Hello Sunday at www.us.hellosundayspf.com and on Instagram at @hellosundayspfRated #1 Best Beauty Business Podcast on FeedPostThis episode is brought to you by WavebreakLeading direct-to-consumer brands hire Wavebreak to turn email marketing into a top revenue driver.Most eCommerce brands don't email right... and it costs them. At Wavebreak, our eCommerce email marketing agency helps qualified brands recapture 7+ figures of lost revenue each year.From abandoned cart emails to Black Friday campaigns, our best-in-class team manage the entire process: strategy, design, copywriting, coding, and testing. All aimed at driving growth, profit, brand recognition, and most importantly, ROI.Curious if Wavebreak is right for you? Reach out at Wavebreak.co

Federico, Isabel González y Teresa de la Cierva hablan del melanoma con las dermatólogas María Vitale y Natividad Cano.

In this episode of Feel Better, Feel Great, Dr. Andrea McSwain explores the deeper layers of skin cancer, toxic burden, and the powerful connection between your internal health and skin. Learn how to identify the three main types of skin cancer—basal cell, squamous cell, and melanoma—while discovering how detox pathways, inflammation, oxidative stress, and conventional skincare products contribute to skin damage. Packed with holistic prevention strategies like clean beauty swaps, anti-inflammatory nutrition, natural sun protection, and daily detox support, this episode empowers you to protect your skin from the inside out. Tune in to decode your body's signals, reduce your toxic load, and embrace radiant, resilient skin. #skincancerawareness #HolisticSkincare #DetoxYourSkin #FunctionalMedicine #NaturalHealth #OxidativeStress #ToxicBurden #CleanBeauty #AntiInflammatoryLifestyle

Welcome to another episode of the VJ Oncology Podcast, where we bring you the forefront of cancer research and clinical... The post Expanding Cell Therapy – TILs, TCRs & CARs in Lung Cancer and Melanoma appeared first on VJOncology.

Dr. Marc Hurlbert discusses melanoma prevention, Dave Thompson reviews the news, Matt Olien critiques Clown in a Cornfield, and we explore Arctic archaeology.

ເຖິງແມ່ນວ່າຈະມີການຣົນນະຣົງໃນການປ້ອງກັນມະເຮັງຜິວໜັງໃນ ອອສເຕຣເລັຍ ເປັນເວລາຫຼາຍສິບປີແລ້ວ, ແຕ່ຊາວໜຸ່ມສມັຍນີ້ຍັງ ບໍ່ມີຄວາມຕື່ນໂຕ ຕໍ່ ອັນຕະຣາຍຂອງ ໂຣກນີ້. ຜູ້ຊ່ຽວຊານກ່າວວ່າ ອິດທິພົນຂອງ ສື່ສານມວນຊົນ ເປັນສາເຫດຫຼັກຂອງປັນຫານີ້.

Are you or a loved one facing a diagnosis of bladder cancer, melanoma, or skin cancer? Tune in to this essential episode of Navigating Cancer TOGETHER for expert guidance and compassionate insights. Join host Talaya Dendy as she welcomes back Dr. Thomas Eanelli, a highly respected radiation oncologist based in New York. We also feature Angel Santana, co-host of The CROC Podcast, sharing powerful motivational perspectives. In observance of May Cancer Awareness, this special episode dives into critical aspects of three specific cancers: bladder, melanoma, and skin cancer. Dr. Eanelli provides invaluable medical expertise on the latest cancer treatments, diagnosis, and management of these diseases. Angel Santana offers heartfelt inspiration and emphasizes the power of support and positivity throughout the cancer journey. This episode is packed with vital information and moving stories to offer hope and guidance for anyone navigating cancer.

La incidencia del melanoma en España continúa al alza. El Registro Nacional de melanoma de la Academia Española de Dermatología y Venereología avanza en sus estudios sobre el melanoma, tal y como explica el Dr. Rafael Botella, miembro de la Academia Española de Dermatología, que acaban de dirigir su congreso nacional en Valencia.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFB865. CME/MOC/AAPA/IPCE credit will be available until April 27, 2026.Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFB865. CME/MOC/AAPA/IPCE credit will be available until April 27, 2026.Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFB865. CME/MOC/AAPA/IPCE credit will be available until April 27, 2026.Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFB865. CME/MOC/AAPA/IPCE credit will be available until April 27, 2026.Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Maggio è il mese della sensibilizzazione del melanoma e dei tumori della pelle, un’occasione preziosa per fare il punto su come prenderci cura della nostra pelle sotto il sole. Lo sapevate che bastano 5 scottature tra i 15 e i 20 anni per aumentare dell’80% il rischio di melanoma? In questa puntata di Obiettivo Salute risveglio parliamo di prevenzione con il professor Paolo Ascierto, tra i massimi esperti italiani in oncologia dermatologica. Scopriremo insieme i sette errori più comuni che commettiamo con il sole – dall’uso di creme solari scadute alla convinzione di potersi abbronzare “in sicurezza” – ma anche perché il sole non è solo un nemico, se impariamo a rispettarlo. Un viaggio informativo per imparare a godere del sole… senza scottature.

Listen to today's podcast... Are you protected from the sun under an umbrella? How about on a cloudy day? Do you think you're protected from the sun under the water? Does a baseball cap protect you from the sun? Are you protected from the sun if you go to a tanning salon first? Not sure of the answers, then you need to find out, as it could save your life. Melanoma is the deadliest form of skin cancer since it's more likely to spread to other parts of the body. It is increasing in both men and women. Non-melanoma skin cancer, a less deadly type of skin cancer, is the most commonly occurring cancer, accounting for about one-third of all cancer cases. Take One Action Today To Build Your #Resiliency!      So Here are today's Tips For Building Resiliency and Celebrating National Sun Awareness Week: Reduce sun exposure between 11am and 4pm. Seek shade or create your own shade. Think Slip – Slap – Slop Slip! on clothing to protect your arms and legs. Slap! on a wide-brimmed hat. Slop! on sunscreen with SPF #15 or higher. Be Prepared and Stay Safe In The Sun Remember, If you like today's wellness tips, let me know. You can leave me a review on amazon or through your #alexa app. Looking for more tips to build your resiliency? Look for my book on Amazon called Stress Out. 52 Weeks To Letting More Life In #mentalhealth #hr

Originally broadcast May 8, 2025 Skin cancer is the most common cancer in the United States, and melanoma is its deadliest form. Cases have tripled in the past 30 years, particularly among younger people — even as rates for other common cancers have gone down. Marc Hurlbert, Ph.D., CEO of the Melanoma Research Alliance (MRA), joins “Conversations on Health Care” hosts Mark Masselli and Margaret Flinter to talk about the urgent need for more research, the role of philanthropy, and... Read More Read More The post Menacing Melanoma: Marc Hulbert, PhD on How You Can Fight Back appeared first on Healthy Communities Online.

Host Dr. Davide Soldato and guest Dr. Harriet Kluger discuss the JCO article "Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, Medical Oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author Dr. Harriet Kluger. Dr. Kluger is a professor of medicine at Yale School of Medicine, Director of the Yale SPORE in Skin Cancer, and an internationally recognized expert in immuno-oncology for melanoma and renal cell carcinoma. She leads early-phase and translational trials that pair novel immunotherapies with predictive biomarkers to personalized care. Today, Dr. Kluger and I will be discussing the article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases." In this study, Dr. Kluger and colleagues evaluated four cycles of pembrolizumab plus the anti-VEGF antibody bevacizumab followed by pembrolizumab maintenance in patients with asymptomatic non-hemorrhagic melanoma brain metastases that had not previously received PD-1 therapy. Thank you for speaking with us, Dr. Kluger. Dr. Harriet Kluger Thank you for inviting me. The pleasure is really all mine. Dr. Davide Soldato So to kick off our podcast, I just wanted to ask if you could outline a little bit the biological and clinical rationale that led you to test this type of combination for patients with untreated brain metastases from metastatic melanoma. Dr. Harriet Kluger Back in approximately 2012, patients who had untreated brain metastases were excluded from all clinical trials. So by untreated, I mean brain metastases that had not received local therapy such as surgery or radiation. The reason for it was primarily because there was this fear that big molecules wouldn't penetrate brain lesions because they can't pass the blood-brain barrier. Turns out that the blood-brain barrier within a tumor is somewhat leaky and drugs sometimes can get in there. When PD-1 inhibitors were first identified as the next blockbuster class of drugs, we decided to conduct a phase 2 clinical trial of pembrolizumab monotherapy in patients with untreated brain metastases. We actually did it also in lung cancer, and we could talk about that later on. Responses were seen. The responses in the brain and the body were similar. They were concordant in melanoma patients. Now, at approximately that time, also another study was done by the Australian group by Dr. Georgina Long, where they did a randomized trial where patients who didn't require immediate steroid therapy received either nivolumab alone or nivolumab with ipilimumab, and the combination arm was substantially superior. Subsequently, also, Bristol Myers Squibb also conducted a large phase 2 multicenter trial of ipilimumab and nivolumab in patients with untreated brain metastases. And there, once again, they saw that the responses in the brain were similar to the responses in the body. Now, somewhere along the line there, we completed our anti-PD-1 monotherapy trial. And when we looked at our data, we still didn't have the data on ipilimumab and nivolumab. And our question was, “Well, how can we do better?” Just as we're always trying to do better. We saw two really big problems. One was that patients had a lot of perilesional edema. And the other one was that we were struggling with radiation necrosis in lesions that were previously Gamma Knifed. The instance of radiation necrosis was in excess of 30%. So the rationale behind this study was that if we added bevacizumab, maybe we could treat those patients who had some edema, not requiring steroids, but potentially get them on study, get that PD-1 inhibitor going, and also prevent subsequent radiation necrosis. And that was the main rationale behind the study. We had also done some preclinical work in mouse models of melanoma brain metastases and in an in vitro blood-brain barrier model where we showed that bevacizumab, or anti-VEGF, really tightens up those leaky basement membranes and therefore would be very likely to decrease the edema. Dr. Davide Soldato Thank you very much for putting in context the combination. So this was a phase 2 trial, and you included patients who had at least one lesion, and you wanted lesions that were behind 5 and 20 millimeters. Patients could be included also if the brain metastasis was higher in dimension than 20 millimeters, but it had to be treated, and it was then excluded from the evaluation of the primary objective of the trial. So regarding, a little bit, these characteristics, do you think that this is very similar to what we see in clinical practice? And what does this mean in terms of applicability of these results in clinical practice? Dr. Harriet Kluger So that's an excellent question. The brain metastasis clinical research field has somewhat been struggling with this issue of inclusion/exclusion criteria. When we started this, we showed pretty clearly that 5 to 10 millimeter lesions, which are below the RECIST criteria for inclusion, are measurable if you use MRIs with slices that are 1 to 2 millimeters. Most institutions in the United States do use these high-resolution MRIs. I don't know how applicable that is on a worldwide scale, but we certainly lowered the threshold for inclusion so that patients who have a smattering of small brain metastases would be eligible. Now, patients with single large brain metastases, the reason that we excluded those from the trial was because we were afraid that if a patient didn't respond to the systemic therapy that we were going to give them, they could really then develop severe neurological symptoms. So, for patient safety, we used 20 millimeters as the upper level for inclusion. Some of the other trials that I mentioned earlier also excluded patients with very large lesions. Now, in practice, one certainly can do Gamma Knife therapy to the large lesions and leave the smaller ones untreated. So I think it actually is very applicable to clinical practice. Dr. Davide Soldato Thank you very much for that insight, because I think that sometimes criteria for clinical trials, they have to be very restrictive. But then we know that in clinical practice, the applicability of these results is probably broader. So, going a little bit further in the results of the study, I just wanted a little bit of comment from you regarding what you saw in terms of intracranial response rate and duration of response among patients who obtained a response from the combination treatment. Dr. Harriet Kluger So we were actually surprised. When we first designed this study, as I said earlier, we weren't trying to beat out ipilimumab and nivolumab. We were really just trying to exclude those patients who wouldn't have otherwise been eligible for ipilimumab and nivolumab because of edema or possibly even previous radiation necrosis. So it was designed to differentiate between a response rate of 34%, and I believe the lower bound was somewhere in the 20s, because that's what we'd seen in the previous pembrolizumab study. What we saw in the first 20 patients that we enrolled was actually a response rate that far exceeded that. And so we enrolled another cohort to verify that result because we were concerned about premature publishing of a result that we might have achieved just by chance. The two cohorts were very similar in terms of the response rates. And certainly this still needs to be verified in a second study with additional institutions. We did include the Moffitt Cancer Center, and the response rate with Moffitt Cancer Center was very similar to the Yale Cancer Center response rate. Now, your other question was about duration of response. So the other thing that we started asking ourselves was whether this high response rate was really because the administration of the anti-VEGF will decrease the gadolinium enhancement and therefore we might actually just be seeing prettier scans but not tumor shrinkage. And the way to differentiate those two is by looking at the duration of the response. Median progression-free survival was 2.2 years. That's pretty long. The upper bound on the 95% confidence interval was not reached. I can't tell you that the duration is as good as the duration would be when you give ipilimumab. Perhaps it is less good. This was a fairly sick population of patients, and it included some who might not have been able to receive ipilimumab and nivolumab. So it provides an alternative. I do believe that we need to do a randomized trial where we compare it to ipilimumab and nivolumab, which is the current standard of care in this patient population. We do need to interpret these results with caution. I also want to point out regarding the progression-free survival that we only gave four doses of anti-VEGF. So one would think that even though anti-VEGF has a long half-life of three or four weeks, two years later, you no longer have anti-VEGF effect, presumably. So it does something when it's administered fairly early on in the course of the treatment. Dr. Davide Soldato So, in terms of clinical applicability, do you see this combination of pembrolizumab and bevacizumab - and of course, as we mentioned, this was a phase 2 trial. The number of patients included was not very high, but still you saw some very promising results when compared with the combination of ipilimumab and nivolumab. So do you see this combination as something that should be given particularly to those patients who might not be able to receive ipilimumab and nivolumab? So, for example, patients who are very symptomatic from the start or require a high dose of steroids, or also to provide a quicker response in terms of patients who have neurological symptoms, or do you think that someday it could be potentially used for all patients? Dr. Harriet Kluger The third part of your question, whether it can be used someday for all patients: I think we need to be very careful when we interpret these results. The study was substantially smaller than the ipilimumab/nivolumab trial that was conducted by Bristol Myers Squibb. Also going to point out that was a different population of patients. Those were all frontline patients. Here we had a mix of patients who'd had previous anti-CTLA-4 and frontline patients. So I don't think that we can replace ipilimumab and nivolumab with these results. But certainly the steroid-sparing aspect of it is something that we really need to take into consideration. A lot of patients have lesions in locations where edema can be dangerous, and some of them have a hard time coming off the steroids. So this is certainly a good approach for those folks. Dr. Davide Soldato And coming back to something that you mentioned in the very introduction, when you said that there were two main problems, which was one, the problem of the edema, and the second one, the problem of the radionecrosis. In your trial, there was a fair percentage of patients who received some type of local treatment before the systemic one. So the combination of pembrolizumab and bevacizumab. And most of the patients received radiosurgery. So I just wanted a brief comment regarding the incidence of radionecrosis in the trial and whether that specific component of the combination with bevacizumab was reduced. And how do you think that this fares in terms of what we see in clinical practice in terms of radionecrosis? Dr. Harriet Kluger I'm not sure that we really reduced the incidence of radiation necrosis. We saw radiation necrosis here. We saw less of it than in the trial of pembrolizumab monotherapy, but these were also different patients, different time. We saw more than we thought that we were going to see. It was 27%, I believe, which is fairly high still. We only gave the four doses of bevacizumab. Maybe to really prevent radiation necrosis, you have to continue to give the bevacizumab. That, too, needs to be tested. The reason that we gave the four doses of bevacizumab was simply because of the cost of the bevacizumab at the time. Dr. Davide Soldato Thank you very much for that comment on radionecrosis. And I really think that potentially this is a strategy, so continuing the bevacizumab, that really makes a lot of sense, especially considering that the tolerability of the regimen was really very, very good, and you didn't see any significant or serious adverse events related to bevacizumab. So just wondering if you could comment a little bit on the toxicities, whether you had anything unexpected. Dr. Harriet Kluger There was one patient who had a microperforation of a diverticulum, which was probably related to the bevacizumab. It was conservatively managed, and the patient did fine and actually remains alive now, many years later. We had one patient who had dehiscence of a previous wound. So there is some. We did not see any substantial hypertension, proteinuria, but we only gave the four doses. So it is possible that if you give it for longer, we would see some side effects. But still, relative to ipilimumab, it's very, very well tolerated. Dr. Davide Soldato Yeah, exactly. I think that the safety profile is really different when we compare the combination of ipilimumab/nivolumab with the pembrolizumab/bevacizumab. And as you said, this was a very small trial and probably we need additional results. But still, these results, in terms of tolerability and safety, I think they are very interesting. So one additional question that I think warrants a little bit of comment on your part is actually related to the presence of patients with BRAF mutation and, in general, to what you think would be the best course of treatment for these patients who present with the upfront brain metastases. So this, it's actually not completely related to the study, but I think that since patients with BRAF mutation were included, I think that this warrants a little bit of discussion on your part. Dr. Harriet Kluger So we really believe that long-term disease control, particularly in brain metastases, doesn't happen when you give BRAF/MEK inhibitors. You sometimes get long-term control if you've got oligometastatic disease in extracranial sites and if they've previously been treated with a lot of immune checkpoint inhibitors, which wasn't the case over here. So a patient who presents early in the course of the disease, regardless of their BRAF status, I do believe that between our studies and all the studies that have been done on immunotherapy earlier in the course of disease, we should withhold BRAF/MEK inhibitors unless they have overwhelming disease and we need immediate disease control, and then we switch them very quickly to immunotherapy. Can I also say something about the toxicity question from the bevacizumab? I have one more comment to make. I think it's important. We were very careful not to include patients who had overt hemorrhage from brain metastases. So melanoma brain metastases relative to other tumor types tend to bleed, and that was an exclusion criteria. We didn't see any bleeding that was attributable to the bevacizumab, but we don't know for sure that, if this is widely used, that that might not be a problem that's observed. So I would advise folks to use extreme caution and perhaps not use it outside of the setting of a clinical trial in patients with overt hemorrhage in the melanoma brain metastases. Dr. Davide Soldato Thank you very much. I think that one aspect that is really interesting in the trial is actually related to the fact that you collected a series of biomarkers, both circulating ones, but also some that were collected actually from the tissue. So just wondering if you could explain a little bit which type of biomarkers you evaluated and whether you saw any significant results that could suggest higher or lower efficacy of the combination. Dr. Harriet Kluger Thank you for that. So yes, the biomarker studies are fairly exploratory, and I want to emphasize that we don't have anything that's remotely useful in clinical practice at this juncture. But we did see an association between vessel density in the tumors and improved response to this regimen. So possibly those lesions that are more vascular are more fed by or driven by VEGF, and that could be the reason that there was improved response. We also saw that when there was less of an increase in circulating angiopoietin-2 levels, patients were more likely to respond. Whether or not that pans out in larger cohorts of patients remains to be determined. Dr. Davide Soldato Still, do you envision validation of these biomarkers in a potentially additional trial that will evaluate, again, the combination? Because I think that the signals were quite interesting, and they really make sense from a biological point of view, considering the mechanism of action of bevacizumab. So I think that, yeah, you're right, they are exploratory. But still, I think that there is very strong biological rationale. So really I wanted to congratulate you on including that specific part and on reporting it. And so the question is, really, do you envision validation of these biomarkers in larger cohorts? Dr. Harriet Kluger I would hope to see that, just as I'd like to see validation of the clinical results as well. The circulating biomarkers are very easy to do. It's a simple ELISA test. And the vessel density on the tumor is essentially CD34 staining and units per area of tumor. Also very simple to do. So I'd love to see that happen. Dr. Davide Soldato Do you think that considering the quality of the MRI that we are using right now, it would be possible to completely bypass even the evaluation on the tissue? Like, are we going in a direction where we can, at a certain point, say the amount of vessels that we see in these metastases is higher versus lower just based on MRI results? Dr. Harriet Kluger You gave me an outstanding idea for a follow-up study. I don't know whether you can measure the intensity of gadolinium as a surrogate, but certainly something worth asking our neuroradiology colleagues. Excellent idea. Thank you. Dr. Davide Soldato You're welcome. So just moving a step further, we spoke a lot about the validation of these results and the combination. And just wanted your idea on what do you think it would be more interesting to do: if designing a clinical trial that really compares pembrolizumab/bevacizumab with ipilimumab and nivolumab or going directly for the triplet. So we know that there has been some type of exploration of triplet combination in metastatic melanoma. So just your clinical impression: What would you do as an investigator? Dr. Harriet Kluger So it's under some discussion, actually. It's very difficult to compare drugs from different companies in an investigator-initiated trial. Perhaps our European colleagues can do that trial for us. In the United States, it's much harder, but it can be done through the cooperative groups, and we are actually having some discussions about that. I don't have the answer for you. It would be lovely to have a trial that compared the three drugs to ipi/nivo and to pembrolizumab/bevacizumab. So a three-arm trial. But remember, these are frontline melanoma patients. There aren't that many of them anymore like there used to be. So accrual will be hard, and we have to be practical. Dr. Davide Soldato Yeah, you're right. And in the discussion of the manuscript, you actually mentioned some other trials that are ongoing, especially one that is investigating the combination of pembro and lenvatinib, another one that is investigating the combination of nivolumab and relatlimab. So just wondering, do you think that the molecule in terms of VEGF inhibition, so bevacizumab versus lenvatinib, can really make a difference or is going to be just a mechanism of action? Of course, we don't have the results from this trial but just wondering if you could give us a general comment or your opinion on the topic. Dr. Harriet Kluger So that's a really great question. The trial of pembrolizumab and lenvatinib was our answer to the fact that bevacizumab is not manufactured by the same company as pembrolizumab, and we're trying to give a practical answer to our next study that might enable us to take this approach further. But it does turn out from our preclinical studies that bevacizumab and VEGF receptor inhibition aren't actually the same thing in terms of the effects on the blood-brain barrier or the perilesional tumor microenvironment in the brain. And these studies were done in mice and in in vitro models. Very different effects. The lenvatinib has stronger effect on the tumors themselves, the tumor cells themselves, than the bevacizumab, which has no effect whatsoever. But the lenvatinib doesn't appear to tighten up that blood-brain barrier. Dr. Davide Soldato Thank you. I think that's very interesting, and I think it's going to be interesting to see also results of these trials to actually improve and give more options to our patients in terms of different mechanism of action, different side effects. Because in the end, one thing that we discussed is that some combination may be useful in some specific clinical situation while others cannot be applicable, like, for example, an all immunotherapy-based combination. Just one final comment, because I think that we focused a lot on the intracranial response and progression-free survival. You briefly mentioned this but just wanted to reinforce the concept. Did you see any differences in terms of intracranial versus extracranial response for those patients who also had extracranial disease with the combination of pembro and bevacizumab? Dr. Harriet Kluger So the responses were almost always concordant. There were a couple of cases that might have had a body response and not an intracranial response and vice-versa, but the vast majority had concordant response or progression. We do believe that it's a biological phenomenon. The type of tumor that tends to go to the brain is going to be the type of tumor that will respond to whatever the regimen is that we're giving. In the previous trial also, we saw concordance of responses in the body and the brain. Dr. Davide Soldato Thank you very much. Just to highlight that really the combination is worth pursuing considering that there was not so much discordant responses, and the results, even in a phase 2 trial, were very, very promising. So thank you again, Dr. Kluger, for joining us today and giving us a little bit of insight into this very interesting trial. Dr. Harriet Kluger Thank you for having me. Dr. Davide Soldato So we appreciate you sharing more on your JCO article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases," which gave us the opportunity to discuss current treatment landscape in metastatic melanoma and future direction in research for melanoma brain metastasis. If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In this episode of 'Conversations in Lung Cancer Research,' Professor Tom John from the Peter MacCallum Cancer Centre in Melbourne discusses the significant progress and excitement surrounding cancer vaccines, particularly their emerging role in lung cancer treatment.He is joined by Professor Ken O'Byrne, a medical oncologist and clinical scientist at the Princess Alexandra Hospital and Queensland University of Technology, and Professor Georgina Long AO, the medical director of the Melanoma Institute of Australia and co-recipient of the 2024 Australian of the Year.The experts delve into technological advances spurred by COVID-19 vaccine development, promising results from recent melanoma and lung cancer vaccine trials, and the potential for personalised neoantigen mRNA vaccines. They also discuss historical challenges in vaccine efficacy and the promising future of immunotherapy and cancer vaccines, including patient perspectives and the logistics of rapid vaccine production and distribution.00:00 Introduction03:15 Historical Context of Cancer Vaccines05:13 Technological Advances in Vaccine Development06:53 The Promise of mRNA Technology14:03 Personalised vs. Off-the-Shelf Vaccines18:02 Identifying Neoantigens for Vaccines21:13 Caution and Optimism in Vaccine Development23:18 Exploring Tumour Mutation Burden and Vaccine Bias29:35 Challenges and Opportunities in Metastatic Disease33:53 Immunotherapy and Vaccine Hesitancy37:52 Future of Cancer Vaccines and Rapid Innovation42:14 Conclusion and Final Thoughts

Jason talks with dermatologist Dr. Mohiba Tareen about skin cancer awareness month and the simple steps you can take to prevent a deadly form of cancer.

3pm Hour: Jason talks about some of the latest controversy surrounding President Trump. Is the President just trolling people? Then he's joined by dermatologist Dr. Mohiba Tareen to talk about skin cancer awareness month.

In today's episode, supported by Replimune, we had the pleasure of speaking with Anna C. Pavlick, BSN, MSc, DO, MBA, about the use of RP1 plus nivolumab (Opdivo) for the treatment of patients with advanced melanoma. Dr Pavlick is a professor of medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine in New York, New York; as well as the founding director of the Cutaneous Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian. In our exclusive interview, Dr Pavlick discussed the rationale for investigating this combination in patients with advanced melanoma who have received prior immune checkpoint inhibition, key efficacy and safety findings from the phase 1/2 IGNYTE trial (NCT03767348), and where the future may be headed regarding the use of oncolytic viruses in melanoma.

Melanoma treatment has advanced significantly over the past decade, and it continues to evolve. In this special Melanoma Monday episode, we are joined by Kendra Rodriguez, PharmD, PGY2 Oncology Pharmacy Resident at UW Medical Center / Fred Hutchinson Cancer Center, to explore where we are now in the treatment landscape—and what's on the horizon.Kendra walks through recent data from the NADINA and SWOG S1801 trials, and shares how care teams can start preparing for the shift in management to the neoadjuvant setting. You'll hear what it takes to manage complex therapies for resectable cutaneous melanoma, and how to engage patients through thoughtful communication and collaboration.CE Activity Description:The purpose of this CE activity is to describe the pathophysiology and literature behind the shift of pharmacotherapeutic management to the neoadjuvant setting in resectable cutaneous melanoma. As novel mechanisms have been sought after and approved within this disease state, attention will be given to assess the clinical utility of the first-in-class tumor-infiltrating lymphocyte, lifileucel, in addition to its logistical considerations requiring multidisciplinary coordination.Learning Objectives:Summarize the pathophysiology behind neoadjuvant treatment in cutaneous melanoma and the literature supporting its useDiscuss the novel agent lifileucel for its efficacy in cutaneous melanoma treatment and the logistics related to its useDisclosures:No relevant financial relationships for the following faculty and reviewers:• Kendra Gee-Rodriguez, PharmD• Ginger Blackmon, PharmD• Daisy Doan, PharmDClaim credit: https://www.lecturepanda.com/r/CutaneousMelanoma

Listen to today's podcast... Love this advice…If your shadow is shorter than you are, you should seek the shade. Do you annually check your skin?  Wear your sunscreen faithfully?  Do you go and see your doctor for regular check ups? If so, you are helping to ensure that you prevent skin cancer or at least ensure that you catch it in its early stages. The spring is an easy time to forget to use your sunscreen. It is essential that we protect ourselves and our kids and know the early signs of Melanoma, that way we can all be safe in the sun.  Take One Action Today To Build Your #Resiliency!      So Here are today's Tips For Building Resiliency and Celebrating Melanoma Monday…and Being Safe In The Sun Check it out.  Melanoma can be found anywhere on the body, but it is most common on the legs, back, head and neck. Do an annual scan to check for changes. Visit your doctor regularly and make sure that they do a body scan too. Be safe in the sun.  Enjoy the spring, summer and fall sunshine, but cover up and use your sunscreen. Cancer changes lives, impacts families and hinders workplace productivity. Employees coming back to work after cancer treatments describe a variety of challenges that employers may not be aware of/or consider in their return-to-work accommodations. As a leader, look for ways to educate on prevention and look for ways to successfully support a team member who has been impacted. Looking for more ways to build your resiliency, take my free on-line vulnerability test at worksmartlivesmart.com under the resources and courses tab. #mentalhealth #hr

May 5th is Melanoma Monday. A new study led by McGill University shows that Canadians are using less skin/UV protection when outside in the sun. Dr. Ivan Litvinov is senior study author and Associate Professor of Dermatology at McGill University and he spoke to Andrew Carter.

Innovations in Melanoma Treatment: The Role of TIL Therapy with guest Dr. Harriet Kluger May 4, 2025 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

In this episode, our hosts, Megan and Danet, sit down with special guest Ashley McCrary, founder of the Eye on Grace Foundation.

During this episode, our hosts Dr. Jennifer Mabry and Dr. Emily Lee sit down with Amber Hoffert to recognize National Melanoma and Skin Cancer Awareness Month. Hear about the risks of Melanoma, the importance of taking care of your skin, signs to look for, and more! Listen To The Local Matters Podcast Today! News Talk 94.1

Send us a textWelcome to Episode 29 of The Oncology Podcast's Experts On Point series, brought to you by The Oncology Network. Hosted by Rachael Babin.How do we tackle inequities in cancer care? What role do collaborative networks play in ensuring better outcomes for patients and their families? And how can molecular tumour boards bridge the gap for those outside metropolitan areas, giving them access to life-saving treatments and clinical trials?To explore these critical questions, our Host Rachael Babin is joined by Professor Mark Shackleton—Director of Oncology at Alfred Health, Professor of Oncology at Monash University, Chair of Melanoma and Skin Cancer Trials Ltd, and Co-Director of the Monash Partners Comprehensive Cancer Consortium (MPCCC).The Monash Partners Comprehensive Cancer Consortium (MPCCC) is transforming cancer care by creating networks that ensure equitable access to precision oncology across Victoria, regardless of a patient's location.Did You Know?• The MPCCC Fellowship program embeds early-career oncologists in partner hospitals to build expertise and connections• The Precision Oncology Program has processed over 1,000 patient referrals• 20% of referred patients receive recommendations for targeted therapies matched to their cancer's molecular profile• 5% of patients connected to clinical trials they wouldn't otherwise access• Regular molecular tumour boards discuss 5-10 cases per session• MPCCC has delivered a significant increase in regional cancer patient referrals, especially from GippslandVisit our website for information on the simple referral process through the Omico CaSP program and access this incredible resource for your patients. So, let's dive into the groundbreaking work being done to break down barriers and expand access to precision oncology.We hope you enjoy listening.For news and podcast updates subscribe to The Oncology Newsletter,  a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK... Join Us

Join melanoma authority Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, as he navigates the latest breakthroughs in immunotherapy and targeted treatments transforming outcomes for patients with melanoma. Discover how predictive biomarkers, strategic combination therapies, and personalized treatment sequencing are revolutionizing care across neoadjuvant, adjuvant, and metastatic settings. This podcast is essential listening for oncology professionals seeking evidence-based approaches to combat this challenging disease affecting over 100,000 Americans annually. Click here to listen to module 2 of this podcast series: [link] Click here to claim your CME/NCPD credit: [link]

In this concluding module, Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, addresses the critical challenges of managing treatment-associated toxicities in the era of advanced melanoma therapies. Discover practical strategies for handling immune-related adverse events, implementing comprehensive supportive care, and optimizing patient education. This podcast is critical for oncology professionals seeking to balance therapeutic efficacy with quality of life for patients receiving cutting-edge immunotherapy and targeted treatments. Click here to go back and listen to module 1 of this podcast series: [link] Click here to claim your CME/NCPD credit: [link]

As tennis players, we know the sun can be just as much of an opponent in our sport from finding the right SPF and avoiding sun damage. Enter BLOQUV.  Founder and sun sport enthusiast, Corina Biton, joins us in this episode to help educate us on all things UPF apparel. As someone who loves to run, walk, paddleboard and play tennis.  After noticing white spots on my arms, she founded BloqUV when finding skin damage even though she always wore long-sleeve T-shirts. Turns out plain T-shirts only block 5% of the sun's rays! Corina created BloqUV with BloqTek, their proprietary fabric with minimum Ultraviolet Protection Factor 50 that blocks 98% UVA/UVB rays; the protection is chemical-free, inherent to the fabric and unaffected by laundering. After 15 years, BloqUV has emerged as a market leader in sun protection: unique in design, fit and sun protection technology; they're moisture-wicking and quick-dry, allowing for a wide range of uses on land and water!  Learn even more & stay tuned for a chance to win some BloqUV gear!  If you have any further questions or want to continue the conversation?! Email us at podcast@tennis-warehouse.com   Shop with us for all your TENNIS needs all over the WORLD:

According to the American Cancer Society, approximately 5-and-a-half million cases of non-melanoma skin cancer are diagnosed each year in the US. Many of those cancers are highly preventable. In addition, though, about 100 thousand news cases of melanoma are diagnosed each year, making skin cancer the most common cancer in the US.  Dr. Jeanine Cook-Garard talks with Dr. Bhuvanesh Singh, surgical director of the Skin Cancer Program at the Northwell Health Cancer Institute. A board-certified otolaryngologist and head and neck surgeon with extensive experience in oncological and reconstructive surgery, Dr. Singh has published over 190 articles in major journals, is a co-editor of two medical textbooks, and has received numerous research grants.

Hey Heal Squad! The Roundtable is BACK and this week Maria and the squad are tackling sun myths that'll totally change your morning routine. Think sunglasses protect your eyes? Wait till you hear how ditching them could actually turn back the clock on aging! Plus, could morning sun exposure be your skin's new BFF and not the enemy we've been warned about? The squad spills it all. We're also diving deep into the lymphatic system—aka your body's secret to glowing skin and lasting energy. Dr. Alison and Christina Gomes break down easy lymphatic hacks you'll obsess over (rebounding, anyone?). Dry brushing, bed elevation, and more wellness tips you never knew you needed! Hit play and get ready to rethink everything you thought you knew about the sun, skin, and your energy levels. Trust us, your body will thank you! — HEAL SQUAD SOCIALS IG: https://www.instagram.com/healsquad/ TikTok: https://www.tiktok.com/@healsquadxmaria HEAL SQUAD RESOURCES: Heal Squad Website: https://www.healsquad.com/ Maria Menounos Website: https://www.mariamenounos.com Heal Squad x Patreon: https://www.patreon.com/HealSquad/membership  My Curated Macy's Page: Shop My Macy's Storefront Delete Me: https://bit.ly/43rkHwi   code: SQUAD Prenuvo: Prenuvo.com/MARIA for $300 off HEADLINES & RESOURCES Chart Source: https://academic.oup.com/jnci/article-abstract/97/3/195/2544082 Rubberband hack on TikTok EPISODE RESOURCES: ABOUT MARIA MENOUNOS: Emmy Award-winning journalist, TV personality, actress, 2x NYT best-selling author, former pro-wrestler and brain tumor survivor, Maria Menounos' passion is to see others heal and to get better in all areas of life. ABOUT HEAL SQUAD x MARIA MENOUNOS: A daily digital talk-show that brings you the world's leading healers, experts, and celebrities to share groundbreaking secrets and tips to getting better in all areas of life. DISCLAIMER: This Podcast and all related content ( published or distributed by or on behalf of Maria Menounos or http://Mariamenounos.com and http://healsquad.com ) is for informational purposes only and may include information that is general in nature and that is not specific to you. Any information or opinions provided by guest experts or hosts featured within website or on Company's Podcast are their own; not those of Maria Menounos or the Company. Accordingly, Maria Menounos and the Company cannot be responsible for any results or consequences or actions you may take based on such information or opinions. This podcast is presented for exploratory purposes only. Published content is not intended to be used for preventing, diagnosing, or treating a specific illness. If you have, or suspect you may have, a health-care emergency, please contact a qualified health care professional for treatment.

BUFFALO, NY - April 11, 2025 – A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled “GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells." In this work, first author Diana Crisan and corresponding author Abhijit Basu from the University Hospital Ulm led a team that presents experimental evidence pointing to the protein GSK3β as a key contributor to drug resistance in melanoma. Their findings suggest that GSK3β becomes increasingly active in cancer cells during treatment, helping them survive and adapt despite ongoing therapy with BRAF inhibitors. Melanoma is a type of skin cancer in which nearly half of patients have mutations in the BRAF gene that accelerate tumor growth. While treatments targeting BRAF, known as BRAF inhibitors, initially work well, tumors often find ways to fight back. This research perspective explores how GSK3β, a protein involved in metabolism and cell survival, becomes more active in melanoma cells that develop resistance to BRAF inhibitors. Researchers treated melanoma cells with a common BRAF mutation using Dabrafenib, a widely used BRAF inhibitor. Over time, the cancer cells developed resistance and showed a marked increase in GSK3β levels. This pattern was confirmed across multiple melanoma cell models, suggesting that the finding is consistent and reliable. Importantly, the researchers observed that treating resistant cancer cells with a GSK3β inhibitor significantly reduced their growth. This result suggests that blocking this protein could restore sensitivity to treatment, highlighting GSK3β as a promising therapeutic target and supporting the idea of combining GSK3β inhibitors with existing melanoma therapies. “Remarkably, treatment of BRAFi-resistant melanoma cells with the GSK3 inhibitor LY2090314 for three weeks could overcome resistance and significantly decreased melanoma cell growth, confirming the causal role of GSK3 activation for BRAFi resistance development.” The research perspective adds to ongoing efforts to understand and overcome melanoma drug resistance. It shows that resistance is not driven only by genetic mutations but may also involve adaptive changes in the cell's internal signaling and survival mechanisms. By identifying GSK3β as a potential contributor, the authors offer a new direction for improving the durability of targeted treatments in melanoma. As research continues, GSK3β may be a critical factor in the long-term success of melanoma therapy, particularly for patients who have stopped responding to standard BRAF-targeted drugs. Continue reading: DOI: https://doi.org/10.18632/oncotarget.28711 Correspondence to: Abhijit Basu — abhijit.basu@alumni.uni-ulm.de Video short - https://www.youtube.com/watch?v=G2Tq4_r6xLw Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr. Kristi Gran explains equine Melanoma, the A Home For Every Horse group volunteers are at Barefoot Ranch and stop by for a chat about these great organizations. Plus, weird news hits the laugh track button. Listen in…HORSES IN THE MORNING Episode 3665 – Show Notes and Links:Hosts: Jamie Jennings of Flyover Farm and Glenn the GeekGuest co-host: Lisa WysockyTitle Sponsor: State Line Tack HRN coupon code Get 30% OFF any $129 order. Enter coupon code HRN at checkout. Please note: Some products are not eligible for the add'l discount due to manufacturer restrictions. These are noted in your shopping cart.Guest: Dr. Kristi Gran, Conley & Koontz Vet HospitalGuest: Melissa Kitchen from A Home for Every Horse, Darrith Russell from Barefoot RanchAdditional support for this podcast provided by: Daily Dose Equine, Equine Network, and Listeners Like YouTime Stamps:11:42 – Melissa Kitchen & Darrith Russell24:21 – Dr. Kristi Gran33:55 – Weird NewsSee Our ShowsAbout Us

Dr. Kristi Gran explains equine Melanoma, the A Home For Every Horse group volunteers are at Barefoot Ranch and stop by for a chat about these great organizations. Plus, weird news hits the laugh track button. Listen in…HORSES IN THE MORNING Episode 3665 – Show Notes and Links:Hosts: Jamie Jennings of Flyover Farm and Glenn the GeekGuest co-host: Lisa WysockyTitle Sponsor: State Line Tack HRN coupon code Get 30% OFF any $129 order. Enter coupon code HRN at checkout. Please note: Some products are not eligible for the add'l discount due to manufacturer restrictions. These are noted in your shopping cart.Guest: Dr. Kristi Gran, Conley & Koontz Vet HospitalGuest: Melissa Kitchen from A Home for Every Horse, Darrith Russell from Barefoot RanchAdditional support for this podcast provided by: Daily Dose Equine, Equine Network, and Listeners Like YouTime Stamps:11:42 – Melissa Kitchen & Darrith Russell24:21 – Dr. Kristi Gran33:55 – Weird NewsSee Our ShowsAbout Us

Episode Summary:In this episode of The Patient from Hell, we sit down with Samira and Dr. Samantha, two storytellers who delve into the power of personal narratives, cultural identity, and representation. They share their experiences navigating different spaces, finding their voices, and embracing authenticity. Whether you're interested in storytelling, personal growth, or the intersections of culture and identity, this episode offers deep insights and inspiration.About Our Guest:Dr. Samantha Siegel is an onco-pcp and survivorship physician at Kaiser Permanente. She has survived relapsed/refractory Hodgkin Lymphoma, including an autologous bone marrow transplant in June 2022. This has made her passionate about integrative oncology, AYA survivorship, longterm toxicities, returning to work after cancer and more. Dr. Siegel is the cofounder of PCP-ONC CARES program, a longitudinal cancer survivorship care model beginning at diagnosis and she serves as the current director of Cancer Survivorship for Kaiser San Francisco. She is the host of AIM at Melanoma's supportive cancer care podcast, “Beyond the Clinic.” Dr. Siegel is focused on elevating cancer survivorship to a distinct board certification status. She lives in Davis with her husband, three kids and energetic dog. They enjoy outdoor activities and plant-based living.Key Highlights:[00:10:30] The Power of Storytelling in Identity: Sam and Samira discuss how personal experiences shape the stories we tell and the impact storytelling has on self-identity and cultural understanding.[00:22:45] Challenges in Representation: They share their experiences with representation in the media and the barriers they've faced in telling authentic stories.[00:35:00] Embracing Authenticity in Creative Work: A conversation about the importance of staying true to oneself and how authenticity can lead to more meaningful storytelling and connection.Key Moments:[00:02:15] - Introduction to Sam and Samira[00:10:30] - How personal experiences shape storytelling[00:22:45] - Overcoming challenges in representation[00:35:00] - The impact of authenticity in creative work[00:48:20] - Closing thoughts and takeawaysConnect with Us: Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Resources & Links:This episode was supported by the Patient Centered Outcomes Research Institute (PCORI) and features the PCORI ⁠study⁠ “Effects of a Communication Intervention Randomized Controlled Trial to Enable Goals-of-Care Discussions” by Nina BickellDisclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.This episode was supported by an award from the Patient-Centered Outcomes Research Institute.

This week, we're IN IRELAND Telling Everybody Everything about the follow-up treatment since discovering a second melanoma last Friday. Also, Katherine broke her golden rule and watched not one but TWO femicide documentaries on Netflix. Gabby Petito's case raises lots of red flags to watch out for in potential romantic partners, but what red flags should we watch out for in their parents? Plus, your letters on de-friending a slag, being dumped for liking Katherine Ryan, and one young woman's warning to take melanoma very seriously. x Hosted on Acast. See acast.com/privacy for more information.

In this episode of the EMJ Podcast, Jonathan Sackier sits down with Faranak Kamangar, Chair of Dermatology at Palo Alto Medical Foundation and President of the San Francisco Dermatological Society, to discuss the future of AI and telehealth in dermatology.    Timestamps:  00:00 – Introduction  01:41 – DermGPT: bringing AI to dermatology  07:35 – Why telehealth is here to stay  11:15 – Targeted immunotherapies: what's new?  16:57 – Using media to drive education  22:39 – Precision medicine in melanoma  27:15 – Kamangar's podcast ‘The Future of Dermatology'  31:05 – Three wishes for healthcare  

Interview with Monika Janda, PhD, author of 3D Total-Body Photography in Patients at High Risk for Melanoma: A Randomized Clinical Trial. Hosted by Adewole S. Adamson, MD. Related Content: 3D Total-Body Photography in Patients at High Risk for Melanoma

Interview with Monika Janda, PhD, author of 3D Total-Body Photography in Patients at High Risk for Melanoma: A Randomized Clinical Trial. Hosted by Adewole S. Adamson, MD. Related Content: 3D Total-Body Photography in Patients at High Risk for Melanoma

Beyond the Digest are bonus episodes to the DermSurgery Digest that include reviews of interesting and relevant articles from the Journal of the American Academy of Dermatology (JAAD), British Journal of Dermatology (BJD) and JAMA Dermatology.Articles featured in this episode include: “Part 1: Management of antithrombotic medications in dermatologic surgery.” JAAD + “Part 2: Management of intraoperative and perioperative bleeding.” JAAD“5-fluorouracil 5% cream for squamous cell carcinoma in situ: Factors impacting treatment response.” JAAD“Risk of Death Due to Melanoma and Other Causes in Patients With Thin Cutaneous Melanomas.” JAMA Dermatology “Improved disease-specific survival in lentigo maligna treated with Mohs surgery over wide local excision: a retrospective cohort analysis.” BJD, research letter + “Surviving by a margin: Mohs outperforms wide local excision for lentigo maligna.” BJD, commentary on the research letter“Thin and in situ melanomas of unfavorable prognosis: A retrospective observational analysis of local recurrence, metastasis, and death in early-stage disease.” JAAD“Merkel Cell Carcinoma and Immunosuppression, UV Radiation, and Merkel Cell Polyomavirus.” JAMA Dermatology“Reduction of masseter muscle prominence after treatment with onabotulinumtoxinA: Primary results from a randomized phase 2 study.” JAAD“Improvement of platysma prominence with onabotulinumtoxinA: Safety and efficacy results from a randomized, double-blinded, placebo-controlled phase 3 trial.” JAAD Beyond the Digest Contributors include Naomi Lawrence, MD, Dermatologic Surgery Digital Content Editor; Yesul Kim, MD, Beyond the Digest Co-host; Ami Greene, MD; Tara Jennings, MD; Payvand Kamrani, DO; Sydney Proffer, MD; Kathryn Shahwan, MD; and Yssra Soliman, MD. Your feedback is encouraged. Please contact communicationstaff@asds.net.

In this podcast, we share an update on the diagnosis and care of uveal melanoma from Ocular oncologists Dr. Lauren Dalvin and Dr. Basil Williams.   Subscribe to the podcast:  https://MayoClinicOphthalmology.podbean.com Follow and reach out to us on X and IG: @mayocliniceye

Connect with Vanessa Soul: https://sacredsoulenergetics.com/Power & Power Podcast All Apps: https://pod.link/1713095352 SIGN UP FOR MY ASTROLOGY & BUSINESS EMAIL BLOG HERE: https://bit.ly/4hS5kAJTIMESTAMPS ⏱️1:10 Who are you and who are you not? 3:03 Oksana's journey from Tech to Holistic Health 4:14 Diagnosed with Melanoma6:24 Quantam Biologically - new recongzied science 8:35 Light, Water, & Magnetism12:30 Spiritual, emotional, and physical healing journey 13:18 The Process of Quantum Biology: Using the Mind Movie Technique 18:18 Addressing adrenal fatigue with quantum biology27:12 Addressing constipation and digestive issues with quantum biology33:11 Addressing thyroid imbalances through quantum biology38:03 Sunblock is damaging to your skin 42:39 Skin conditions like psoriasis, Melanoma - you need more Sun 44:49 Work with OksanaABOUT OKSANA HANSEN Oksana Hansen is a certified Applied Quantum Biology Practitioner, CEO & Founder of Quantum Lens Wellness. Developed the Quantum Lens Method to help the body heal naturally using light, water and magnetism. https://www.instagram.com/quantumlenswellness/https://www.youtube.com/channel/UCEa1IaZigpITTyE-rZobGSgwww.quantumlenswellness.comCONNECT W/ VANESSA SOUL https://sacredsoulenergetics.com/IG: https://www.instagram.com/sacred__soul____/ Facebook link https://www.facebook.com/vanessa.spiva.9/Threads https://www.threads.net/@sacred__soul____Power & Power Podcast All Apps: https://pod.link/1713095352 Donate to the Podcast: Sacred Soul Energetics Business Venmo: https://venmo.com/code?user_id=4008578222393358557&created=1739583741.404595&printed=1

I thoroughly enjoy taking deep dives with experts in the realm of quantum and circadian biology. It's one of the few times I get to truly geek out on some of the nuances of mitochondria and how light, water and magnetism impacts our wellness and longevity. Today's guest, Oksana Hansen, ticks all of those boxes and then some, as she has quite the origin story and health journey that led her to becoming a quantum and circadian health expert and, ultimately, a quantum clinician. So not only can she speak from didactic knowledge, but she can also pull from her experience treating clients.Oksana's personal health challenges, including a cancer diagnosis, led her to become an advocate for her own health. This experience propelled her into extensive research, focusing on understanding the root causes of health issues rather than merely addressing symptoms. Her exploration into quantum and circadian biology highlighted the significance of aligning with natural biological rhythms for overall well-being.In addition to her role at Quantum Lens Wellness, Oksana hosts the “Quantum Lens Podcast,” where she discusses topics related to quantum biology, circadian rhythms, and holistic health practices.Through her work, Oksana Hansen continues to inspire and guide individuals towards achieving optimal health by harmonizing with the natural elements of light, water, and magnetism. ​​​​​ If you found the information in today's episode with Oksana Hansen particularly interesting and/or compelling, please share it with a family member, friend, colleague and/or anyone that you think could benefit and be illuminated by this knowledge. Sharing is caring :)As always, light up your health! - Watch this video on YouTube - Return to Nature Retreat (June 26th & 27th) — hosted by Oksana Hansen & Carrie Bennett - Where to learn more from and about Oksana Hansen: Quantum Lens Wellness website   Instagram Facebook Quantum Lens Podcast   - Key Points [1:30] Oksana's background in quantum biology & the upcoming June conference [4:00] Oksana's personal health journey: From corporate executive to health crisis [9:00] The problems with conventional blood work analysis & medical diagnosis [12:30] Melanoma diagnosis, questioning mainstream sun exposure advice [15:00] The role of sunscreen toxicity & oxybenzone recall in skin health [18:00] The transition into quantum biology: Light, water, mitochondria & healing [21:00] Hydration & Mitochondria Can we hydrate without drinking water by improving mitochondrial function? [24:00] Ways to Acquire Electrons for Health Importance of circadian rhythm and the body's natural clock. [26:30] Light, Flicker, and Its Effect on Health Sunlight vs. artificial lighting and how it impacts circadian rhythm. [30:00] Seasonal Sunlight, Vitamin D, & Circadian Biology Does moving between sunny climates disrupt human biology? [33:00] Blue Light Blocking & Flicker Reduction Tools Can similar flicker reduction tools be developed for larger screens? [36:00] Return to Nature Conference Overview Location, event structure, and VIP experiences. [40:00] Importance of mastering thoughts when facing health challenges. [45:00] Overcoming Stubborn Mindsets [48:00] Revisiting Core Wellness Pillars Microbes in nature and their role in immunity. [50:30] Magnetism & Sleep Aids Discussion on magnetic mattress pads and their legitimacy. [54:00] The Quantum Keto Diet [57:30] Final Thoughts & Meditation Practices [1:00:00] The Importance of Slowing Down and Returning to Nature [1:00:30] Practitioner Perspective: Anecdotes from Quantum Biology [1:01:08] Case Study: Overcoming Infertility Through Natural Practices [1:01:45] Simple Biological Adjustments for Fertility [1:02:16] The Simplicity of Quantum Biology [1:02:48] Comparing Quantum Biology with Conventional Medicine [1:03:13] Overcoming Skepticism About Simple Health Solutions [1:03:47] Mindset Shifts and Fear in Medical Perception [1:04:15] Final Thoughts on Quantum Biology and Natural Healing  - Save 25% when you Subscribe & Save to a BioBundle!For a BioBundle, you choose: 1.) Any one BioBlue supplement(BioBlue, BioBlue (SR), BioBlue Leuco, BioBlue Calm, BioBlue Capsules or BioBlue Leuco Capsules)2.) Any one BioC60 supplement (Regular or Concentrated)   The BioBundle automatically saves you 15% on both of the supplements you choose. You save an additional 10% by choosing to Subscribe & Save to that BioBundle. The 25% savings is passed along for every monthly delivery of your BioBundle! No discount code necessary!   To shop the BioBundle, click here! - Dr. Mike's #1 recommendations: Water products: Water & Wellness Grounding products: Earthing.com EMF-mitigating products: Somavedic Blue light-blocking glasses: Ra Optics - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook

Native Americans have a lower risk of developing skin cancer than their white counterparts. But a more comprehensive look at the disease over ten years' time shows gaps in how skin cancer among Native people is counted. It also signals problems in awareness, diagnosis, and treatment among people who live in poverty or in rural areas. We'll look at the links between Native Americans and skin cancer, and get a reminder about what to look for. GUESTS Dr. Anna Chacon (Maya), board certified dermatologist Dr. Rachel Asiniwasis (Plains Cree and Saulteaux First Nations), dermatologist and clinician researcher Melissa Buffalo (Meskwaki Nation), Chief Executive Officer at American Indian Cancer Foundation

Is there a way to treat liver metastasis secondary to uveal melanoma without introducing systemic, treatment-related toxicity? Dr. Altan Ahmed (interventional radiologist at Moffitt Cancer Center) and Dr. Sid Padia (interventional radiologist at UCLA) join guest-host Dr. Kavi Krishnasamy to discuss HEPZATO, a novel device-based treatment for liver metastases from uveal melanoma. --- This podcast is supported by: RADPAD® Radiation Protection https://www.radpad.com/ --- SYNPOSIS Dr. Ahmed and Dr. Padia begin by exploring the design and setup of the HEPZATO clinical trials, while also speaking on patient selection criteria. The doctors then talk through the technical aspects of the intervention. After covering workflow and considerations related to procedure timing and coordination, the doctors go on to discuss drug dosing and optimizing treatment cycles. The episode concludes with current gaps in literature, current and future research aims, and potential future applications of the HEPZATO modality in treating other malignancies such as colorectal cancer. --- TIMESTAMPS 00:00 - Introduction 05:40 - Patient Selection Criteria 09:49 - Workflow 19:17 - Procedure Timing and Coordination 29:39 - Challenges and Considerations in Drug Dosing 32:39 - Optimizing Treatment Cycles and Patient Response 37:56 - Managing Post-Treatment and Adverse Effects 43:43 - Future Research and Gaps in Current Interventions 50:45 - Exploring New Applications for PHP Therapy 55:02 - Conclusion --- RESOURCES Hepzato: https://hepzatokit.com/ FOCUS Trial - Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study: https://pubmed.ncbi.nlm.nih.gov/38704501/ FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A): https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.9510 Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial: https://pubmed.ncbi.nlm.nih.gov/36624292/ Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma: https://pmc.ncbi.nlm.nih.gov/articles/PMC11010739/ Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC7801354/ Southampton group - Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma: https://pmc.ncbi.nlm.nih.gov/articles/PMC10906212/ Leiden group - Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases: https://pubmed.ncbi.nlm.nih.gov/38587534/

Ultrasound cosmetics technologies - with Dr. Nicholas Nikolov! -Pediatric melanoma germline mutations -Swearing for analgesia -Thin melanoma mortality -To sign up for Luke's atopic dermatitis CME activity, go to:impactedu.gathered.com/invite/4QbYEVpbzqWant to donate to the cause? Do so here!
Donate to the podcast: uofuhealth.org/dermasphere
Check out our video content on YouTube:
www.youtube.com/@dermaspherepodcast
and VuMedi!: www.vumedi.com/channel/dermasphere/
The University of Utah's Dermatology
ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -
⁠ Connect with us!
- Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC
- Instagram: dermaspherepodcast
- Facebook: www.facebook.com/DermaspherePodcast/
- Check out Luke and Michelle's other podcast,
SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our
friends at:
- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)
- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn
more dermatology!